ELXMF (Nova Eye Medical) Total Equity: $10.51 Mil (As of Dec. 2025)


ELXMF Nova Eye Medical Ltd ELXMF
55 GF Score
Price $0.01
GF Value $0.02
! 4 Warning Signs
View Full Analysis

What is Nova Eye Medical Total Equity?

Nova Eye Medical ELXMF -0.03% 55 Total Equity is $10.51 Mil as of Dec. 2025. GuruFocus rates ELXMF with a GF Score™ of 55/100 and a GF Value™ of $0.02. The stock has 4 warning signs investors should review.

Nova Eye Medical's total equity for the quarter that ended in Dec. 2025 was $10.51 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Nova Eye Medical Total Equity Historical Data

* Premium members only.

The historical data trend for Nova Eye Medical's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nova Eye Medical Total Equity Chart

Nova Eye Medical Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 27.02 21.36 15.56 14.16 12.35

Nova Eye Medical Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.39 14.16 11.00 12.35 10.51
ELXMF
55GF Score
Nova Eye Medical Ltd ELXMF
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nova Eye Medical Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Nova Eye Medical's Total Equity for the fiscal year that ended in Jun. 2025 is calculated as

Total Equity=Total Assets(Q: Jun. 2025 )-Total Liabilities(Q: Jun. 2025 )
=17.255-4.907
=12.35

Nova Eye Medical's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=15.73-5.216
=10.51

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $10.51 Mil mean?
Nova Eye Medical (ELXMF) has a Total Equity of $10.51 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for Nova Eye Medical and its competitors.
Is Nova Eye Medical's Total Equity too high?
Nova Eye Medical's current Total Equity is $10.51 Mil. Overall, Nova Eye Medical has a GF Score™ of 55/100, reflecting its overall financial health beyond just this single metric.
How does Nova Eye Medical's Total Equity compare to ABT and SYK?
Nova Eye Medical's Total Equity of $10.51 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Medical Devices & Instruments company?
A good Total Equity depends on the Medical Devices & Instruments industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Nova Eye Medical and its competitors. Nova Eye Medical's current Total Equity is $10.51 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nova Eye Medical stock overvalued right now?
Nova Eye Medical (ELXMF) has a current Total Equity of $10.51 Mil. The stock's GF Value™ is $0.02, compared to a current price of $0.01 — trading 28.5% below its estimated fair value. The current Total Equity is $10.51 Mil. Nova Eye Medical's overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Nova Eye Medical (ELXMF), the current Total Equity is $10.51 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nova Eye Medical (ELXMF) Overvalued in 2026?

Based on GuruFocus' analysis, Nova Eye Medical stock appears to be undervalued. The current stock price of $0.01 is trading 28.5% below its estimated GF Value™ of $0.02.

Key valuation signals for ELXMF:

  • Total Equity: $10.51 Mil
  • GF Value™: $0.02 vs. price of $0.01 (28.5% below fair value)
  • GF Score™: 55/100 with 4 warning signs

No single metric tells the full story. See the ELXMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nova Eye Medical Business Description

Other Exchanges EYE:Australia
Address 107 Rundle Street, Kent Town, Adelaide, SA, AUS, 5067
Nova Eye Medical Ltd develops and sells surgical devices for the treatment of glaucoma, a cause of blindness. In addition, the company is involved in the commercialisation of the subthreshold nano-pulse ophthalmic laser, 2RT, for the treatment of retinal disease via the AlphaRET segment. The company's reportable segments are: Glaucoma Surgical Devices and AlphaRET. The majority of its revenue is generated from the Glaucoma Surgical Devices segment, which is involved in the design, manufacture, marketing, and sale of the iTrack, iTrack Advance, and the Molteno3 glaucoma surgical device. These are all single-use surgical devices. Geographically, the company generates maximum revenue from the United States of America, followed by Europe, the Asia Pacific, Other regions, and Australia.
55GF Score

Get the complete analysis for ELXMF

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.01
Price
$0.02
GF Value